Tumor-TargetingSalmonella typhimuriumA1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model
- 20 January 2017
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 118 (8) , 2314-2319
Abstract
Previously, a BRAF-V600E-mutant melanoma obtained from the right chest wall of a patient was grown orthotopically in the right chest wall of nude mice to establish a patient-derived orthotopic xenograft (PDOX) model. Trametinib (TRA), an MEK inhibitor, caused tumor regression. In contrast, another MEK inhibitor, cobimetinib (COB) could slow but not arrest growth or cause regression of the melanoma PDOX. First-line therapy temozolomide (TEM) could slow but not arrest tumor growth or cause regression. In addition, vemurafenib (VEM) was not effective even though VEM is supposed to target the BRAF-V600E mutation. We also previously demonstrated that tumor-targeting with S. typhimurium A1-R combined with TEM was significantly more effective than either S. typhimurium A1-R alone or TEM alone on the melanoma PDOX with the BRAF-V600E mutation. The present study used this PDOX model of melanoma to test its sensitivity to VEM combined with S. typhimurium A1-R compared to VEM alone and VEM combined with COB. VEM combined with S. typhimurium A1-R was significantly more effective than VEM alone or VEM combined with COB (P = 0.0216) which is currently first line therapy for advanced melanoma with a BRAF-V600E mutation. J. Cell. Biochem. 118: 2314–2319, 2017.Keywords
This publication has 45 references indexed in Scilit:
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysisCritical Reviews in Oncology/Hematology, 2016
- Melanin content in melanoma metastases affects the outcome of radiotherapyOncotarget, 2016
- Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma—An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology GroupJournal of Clinical Oncology, 2014
- Comparison of efficacy ofSalmonella typhimuriumA1-R and chemotherapy on stem-like and non-stem human pancreatic cancer cellsCell Cycle, 2013
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain ofSalmonella typhymuriumCell Cycle, 2009
- Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimuriumJournal of Cellular Biochemistry, 2009
- A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens.Proceedings of the National Academy of Sciences, 1992
- Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens.Proceedings of the National Academy of Sciences, 1991